Characteristics and skin cancer risk of psoriasis patients with a history of skin cancer in BADBIR
K.J. Mason,A.D. Burden,J.N.W.N. Barker,M. Lunt,H. Ali,C.E. Kleyn,K. McElhone,M.M. Soliman,A.C. Green,C.E.M. Griffiths,N.J. Reynolds,A.D. Ormerod,Fiona Browne,Ian Evans,Brian Kirby,Linda Lawson,Philip Laws,Teena Mackenzie,Tess McPherson,Ruth Murphy,Caroline Owen,Eleanor Pearson,Josh Richards,Catherine Smith,Richard Warren,Gabrielle Belcher,Anthony Bewley,Simon Morrison,
DOI: https://doi.org/10.1111/jdv.17230
2021-03-29
Journal of the European Academy of Dermatology and Venereology
Abstract:<p>A cohort study of patients with moderate‐severe psoriasis registered to the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) determined that there was no association between developing a first basal cell carcinoma (BCC) or squamous cell carcinoma (SCC) following treatment with biologic therapy when compared to non‐biologic systemic therapies.</p>
dermatology